- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Curasight: Erster Patient in Phase-1-Studie zu Hirntumor-Therapie behandelt | 2 | Investing.com Deutsch | ||
| Do | Curasight doses first patient in phase 1 brain cancer treatment trial | 1 | Investing.com | ||
| Do | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 268 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 14.12. | CURASIGHT: Notice of Extraordinary General Meeting | 1 | Cision News | ||
| 12.12. | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility | 3 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 12.12. | Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility | 1 | Cision News | ||
| 08.12. | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 338 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 28.11. | Curasight to present at HC Andersen Capital | 1 | Cision News | ||
| 27.11. | CURASIGHT: Interim report Q3 2025 | 2 | Cision News | ||
| 26.11. | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 227 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen | |
| 13.11. | Curasight to present at Dansk Aktionærforening InvestorDagen | 3 | Cision News | ||
| 29.10. | Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting | 4 | Cision News | ||
| 01.10. | Curasight announces broadening and extension of patent protection for uTRACE | 1 | Cision News | ||
| 03.09. | Transaction with shares in Curasight A/S made by managerial employee | 1 | Cision News | ||
| 28.08. | CURASIGHT: Half-year report Q2 2025 | 1 | Cision News | ||
| 26.08. | Curasight receives approval for brain cancer treatment trial | 1 | Investing.com | ||
| 26.08. | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 268 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen | |
| 19.03. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 19.03.2025 | 198 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 19.03.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 19.03.2025ISIN NameDK0061295797 CURASIGHT A/S DK -... ► Artikel lesen | |
| 31.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 31.01.2025 | 1.232 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.01.2025
Aktien
1 CA6699882065 Nu E Power Corp.
2... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,20 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,340 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 84,35 | 0,00 % | Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital | ||
| PRAXIS PRECISION MEDICINES | 280,40 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,400 | 0,00 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| EDGEWISE THERAPEUTICS | 20,940 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| IMMUNOME | 22,030 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| IMMUNOVANT | 27,540 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| CG ONCOLOGY | 40,080 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,98 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| JYONG BIOTECH | 4,780 | 0,00 % | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 63,35 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 53,80 | 0,00 % | Vera Therapeutics stock price target raised to $66 by BofA Securities | ||
| BICARA THERAPEUTICS | 18,320 | 0,00 % | Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating |
Das Unternehmen CURASIGHT A/S kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,715 Euro und damit +15,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.